Allstate Corporation’s Voyager Therapeutics VYGR Stock Holding History

Allstate Corporation’s Portfolio VYGR Stock Details VYGR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q3	–	Sell	-7,377	Closed	-$201K	–	538
2019 Q2	$201K	Buy	+7,377	New	+$169K	﹤0.01%	477

Other funds holding VYGR

TGI

TRV GP III Boston, Massachusetts $6.14M AUM 45.44% 1-Year Est. Return

Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return

PHS

PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return

Casdin Capital New York $1.32B AUM 76.62% 1-Year Est. Return

Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Allstate Corporation's VYGR Position: Q3 2019 in Review

Allstate Corporation sold out of Voyager Therapeutics (VYGR) in Q3 2019, closing a stake of 7,377 shares — an estimated $201K sold.

Allstate Corporation first reported a position in VYGR in Q2 2019 and held it in 1 quarter. The position peaked at $201K in Q2 2019. 131 funds tracked by Wall St. Rank hold VYGR as of Q3 2019.

Allstate Corporation reported no remaining Voyager Therapeutics position as of Q3 2019 after selling out during the quarter.
Allstate Corporation sold 7,377 Voyager Therapeutics shares in Q3 2019, an estimated $201K.
Allstate Corporation first reported a position in Voyager Therapeutics in Q2 2019 and held it in 1 quarter.
Allstate Corporation's Voyager Therapeutics position peaked at $201K in Q2 2019.
131 funds tracked by Wall St. Rank held Voyager Therapeutics as of Q3 2019.

Based on Allstate Corporation's 13F filing for Q3 2019, filed 14 Nov 2019.